Lupin has entered into a distribution agreement with Medis for Lupin's orphan drug NaMuscla (mexiletine). Medis will commercialize NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries. NaMuscla is the first and only licensed product for this indication.
Under the agreement, Medis will initially focus on the commercialization of NaMuscla in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase. Lupin will continue commercialization of NaMuscla in Germany, France, and the UK.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
